PRNewsWire
08 Jun 2026, 16:51 UTC · 21w ago
Impact · against what's priced in
GRCE faces significant headwinds following an FDA rejection of its lead candidate GTx-104 and a subsequent fraud investigation. DCO and DOCS are facing separate investigations by the Schall Law Firm, adding governance and legal risk to their profiles.
No priced-in read yet
What the story claims
3 claims · scored −1 bearish … +1 bullish
The FDA issued a Complete Response Letter (CRL) rejecting Grace Therapeutics' New Drug Application for GTx-104.
More negative than 99% of claims this week
The FDA cited deficiencies in product packaging leachables, toxicology risk assessments, and contract manufacturing organization operations.
Continue reading
5 related stories
The FDA's Complete Response Letter for GTx-104, citing manufacturing and toxicology deficiencies, coupled with a legal investigation into securities law violations, creates severe regulatory and financial risk.
Read from the article alone
No priced-in read yet
The Schall Law Firm has launched a fraud investigation into Ducommun Incorporated for potential violations of securities laws.
Read from the article alone
No priced-in read yet
The Schall Law Firm has launched a fraud investigation into Doximity, Inc. for potential violations of securities laws.
Read from the article alone
Scored by the NIS engine · methodology.
Search tags
More negative than 94% of claims this week
The Schall Law Firm has launched a fraud investigation into Grace Therapeutics for potential violations of securities laws.
More negative than 86% of claims this week
Which stocks this story touches
More negative than 99% of ticker scores this week
The company is facing a fraud investigation following an FDA Complete Response Letter and a nearly 46% drop in share price.
More negative than 93% of ticker scores this week
The company is the subject of a fraud investigation by the Schall Law Firm.
More negative than 93% of ticker scores this week
The company is the subject of a fraud investigation by the Schall Law Firm.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
8h ago
−19.6%
Price agrees with the score
$1.85 vs $2.30 close before publication (Jun 5) · not market-adjusted
GRCE chart →−9.8%
Price agrees with the score
$135.25 vs $149.89 close before publication (Jun 5) · not market-adjusted
DCO chart →+57.9%
Price is moving against the score
$32.51 vs $20.59 close before publication (Jun 5) · not market-adjusted
DOCS chart →
